Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.47 USD
+0.09 (6.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.48 +0.01 (0.68%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Company Summary
Menlo Park, CA-based Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA.
PacBio’s products are based on SMRT technology which helps scientists observe the DNA synthesis in real time by harnessing the natural process of DNA replication started by the enzyme DNA polymerase.
In October 2022, PacBio announced two new sequencing platforms — Revio (a new long-read sequencing system designed to enable the ...
Company Summary
Menlo Park, CA-based Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA.
PacBio’s products are based on SMRT technology which helps scientists observe the DNA synthesis in real time by harnessing the natural process of DNA replication started by the enzyme DNA polymerase.
In October 2022, PacBio announced two new sequencing platforms — Revio (a new long-read sequencing system designed to enable the use of HiFi sequencing for large studies in human genetics, cancer research, and agricultural genomics) and Onso (a short-read DNA sequencing system). The company began taking orders for Revio in fourth-quarter 2022. PacBio commenced the beta program for Onso in fourth-quarter 2022 and began taking orders for Onso during first-quarter 2023.
In August 2023, PacBio acquired California-based genomics company, Apton Biosystems, Inc. to integrate its Sequencing by Binding (SBB) short-read chemistry into Apton’s high throughput instrument to offer a differentiated high throughput sequencer.
FY23
PacBio’s 2023 revenues totaled $200.5 million (up 56.3% from FY22).
Product revenues were $183.9 million (91.7% of net revenues, up 69.2% from FY22), while Service and other revenues totaled $16.6 million (8.3%, down 15.1%).
Geographically, PacBio’s revenues from the Americas were $105.4 million (52.6% of net revenues, up 51.5% from FY22), Europe, the Middle East, and Africa were $40.7 (20.3%, up 79.9%) and Asia-Pacific were $54.5 (27.2%, up 50.7%).
General Information
Pacific Biosciences of California, Inc
1305 O`BRIEN DRIVE
MENLO PARK, CA 94025
Phone: 650-521-8000
Fax: 302-636-5454
Web: http://www.pacb.com
Email: ir@pacb.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/9/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.26 |
Current Year EPS Consensus Estimate | -1.00 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/9/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 1.38 |
52 Week High | 14.55 |
52 Week Low | 1.25 |
Beta | 1.83 |
20 Day Moving Average | 12,906,801.00 |
Target Price Consensus | 5.65 |
4 Week | -60.80 |
12 Week | -78.22 |
YTD | -85.01 |
4 Week | -59.61 |
12 Week | -78.83 |
YTD | -85.99 |
Shares Outstanding (millions) | 267.95 |
Market Capitalization (millions) | 393.89 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 22.86% |
vs. Previous Quarter | 0.00% |
vs. Previous Year | 113.35% |
vs. Previous Quarter | 4.79% |
Price/Book | 0.56 |
Price/Cash Flow | NA |
Price / Sales | 1.96 |
3/31/24 | NA |
12/31/23 | -40.23 |
9/30/23 | -43.39 |
3/31/24 | NA |
12/31/23 | -15.24 |
9/30/23 | -15.58 |
3/31/24 | NA |
12/31/23 | 7.81 |
9/30/23 | 4.80 |
3/31/24 | NA |
12/31/23 | 7.21 |
9/30/23 | 4.43 |
3/31/24 | NA |
12/31/23 | -140.41 |
9/30/23 | -170.26 |
3/31/24 | NA |
12/31/23 | -152.97 |
9/30/23 | -182.34 |
3/31/24 | NA |
12/31/23 | -158.67 |
9/30/23 | -188.66 |
3/31/24 | NA |
12/31/23 | 2.62 |
9/30/23 | 3.05 |
3/31/24 | NA |
12/31/23 | 2.32 |
9/30/23 | 1.96 |
3/31/24 | NA |
12/31/23 | 1.27 |
9/30/23 | 1.17 |
3/31/24 | NA |
12/31/23 | 55.99 |
9/30/23 | 53.87 |